Monitor whether the concurrent equity offering closes, as failure of either offering could impact funding for the obexelimab commercial launch. The 130% conversion premium suggests management expects significant stock price appreciation, but the non-contingent structure increases execution risk.
Price Chart
Executive Summary
Zenas BioPharma is conducting a concurrent offering of convertible senior notes and common stock to fund the U.S. commercial launch of obexelimab for IgG4-RD and advance its development pipeline. The company recently secured a $75 million loan tranche and reported positive Phase 3 trial results for IgG4-RD, positioning it for a potential BLA submission in Q2 2026. However, the offering is not contingent on the concurrent equity offering, creating execution risk.
Key Facts
- Offering $X million of convertible senior notes due 2032 with a conversion premium of 130% of the stock price
- Concurrent equity offering of shares at $22.19/share (March 25, 2026 close)
- Net proceeds to fund commercial launch of obexelimab for IgG4-RD and Phase 3 trials for orelabrutinib
- Positive Phase 3 results for IgG4-RD (INDIGO trial) with 56% reduction in flare risk (p=0.0005)
- Loan Agreement provides up to $250 million in tranches, with $75 million tranche A expected in March 2026
- Offering not contingent on concurrent equity offering completion
Financial Impact
Approximately $X million in net proceeds from notes offering, plus $Y million from concurrent equity offering if completed
Risk Factors
- Concurrent equity offering may not close, reducing available capital
- No established market for the notes, limiting liquidity
- Substantial dilution possible upon note conversion
- Company has no approved products and has not generated revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001104659-26-035241 |
| Document: 0001104659-26-035241-index-headers.html | 0001104659-26-035241 |
| Document: 0001104659-26-035241-index.html | 0001104659-26-035241 |
| Document: 0001104659-26-035241.txt | 0001104659-26-035241 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | Press Release | $26.71 | awaiting T+60 | — | $27.51 (+3.00%) |
Oct 13, 2026 14d ago | 8-K | $25.16 | awaiting T+60 | — | $27.51 (+9.34%) |
Sep 22, 2026 5w ago | Press Release | $33.05 | awaiting T+60 | — | $27.51 (−16.76%) |
Sep 18, 2026 5w ago | Press Release | $32.55 | awaiting T+60 | — | $27.51 (−15.48%) |
Sep 11, 2026 6w ago | S-3ASR | $31.91 | awaiting T+60 | — | $27.51 (−13.79%) |
May 28, 2026 21w ago | Press Release | $18.56 $32.29 | ▲ +73.98% | ▲ +72.24% | $27.51 (+48.22%) |
May 19, 2026 23w ago | Press Release | $17.84 $29.20 | ▲ +63.68% | ▲ +57.39% | $27.51 (+54.20%) |
May 13, 2026 23w ago | Press Release | $19.93 $32.43 | ▲ +62.72% | ▲ +58.28% | $27.51 (+38.03%) |
May 13, 2026 23w ago | 8-K | $19.93 $32.43 | ▲ +62.72% | ▲ +58.28% | $27.51 (+38.03%) |
May 13, 2026 23w ago | Press Release | $19.93 $32.43 | ▲ +62.72% | ▲ +58.28% | $27.51 (+38.03%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers